Literature DB >> 29277310

Mechanism of intranasal drug delivery directly to the brain.

Tyler P Crowe1, M Heather West Greenlee1, Anumantha G Kanthasamy1, Walter H Hsu2.   

Abstract

Neurological diseases are becoming increasingly prominent worldwide due to rapidly aging populations, which greatly contributes to increasing healthcare costs. The development of neuroprotective drugs has so far proven exceptionally difficult due to the blood-brain barrier. One novel approach to address this challenge is to administer drugs intranasally to noninvasively bypass the blood-brain barrier. The intranasal route can thus transport drugs directly to the brain from the nasal cavity along the olfactory and trigeminal nerves. The purpose of this review is to describe the details of this mechanism to better direct future research. The intranasal route is composed of two pathways, one being intracellular while the other being extracellular. The intracellular pathway begins with endocytosis by olfactory sensory cells, followed by axonal transport to their synaptic clefts in the olfactory bulb where the drug is exocytosed. This transynaptic process is repeated by olfactory neurons, thereby distributing the drug to other brain regions. In the extracellular mechanism, drugs are transported directly into the cerebral spinal fluid by first passing through the paracellular space across the nasal epithelium, then through the perineural space to the subarachnoid space of the brain. With a growing body of evidence and trials in both rodent and human models, this is an exciting area for research as therapeutics come to market.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood-brain barrier; CNS; Drug delivery; Intranasal; Mechanism; Olfactory nerve; Trigeminal nerve

Mesh:

Year:  2017        PMID: 29277310     DOI: 10.1016/j.lfs.2017.12.025

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  86 in total

1.  Acute intranasal dopamine application counteracts the reversal learning deficit of spontaneously hypertensive rats in an attentional set-shifting task.

Authors:  Jay-Shake Li; Shan-Sung Yang; Joseph P Huston; Owen Y Chao; Yi-Mei Yang; Claudia Mattern
Journal:  Psychopharmacology (Berl)       Date:  2021-05-12       Impact factor: 4.530

Review 2.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

3.  Patient-Friendly, Olfactory-Targeted, Stimuli-Responsive Hydrogels for Cerebral Degenerative Disorders Ensured > 400% Brain Targeting Efficiency in Rats.

Authors:  Noha Nafee; Abd El Rahman Ameen; Osama Y Abdallah
Journal:  AAPS PharmSciTech       Date:  2020-11-22       Impact factor: 3.246

4.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

Review 5.  Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers.

Authors:  Madhur Kulkarni; Niserga Sawant; Anjali Kolapkar; Aishwarya Huprikar; Namita Desai
Journal:  AAPS PharmSciTech       Date:  2021-04-28       Impact factor: 3.246

6.  Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model.

Authors:  Haroldo C de Oliveira; Luna S Joffe; Karina S Simon; Rafael F Castelli; Flavia C G Reis; Arielle M Bryan; Beatriz S Borges; Lia C Soares Medeiros; Anamelia L Bocca; Maurizio Del Poeta; Marcio L Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

7.  Intranasal levosimendan prevents cognitive dysfunction and apoptotic response induced by repeated isoflurane exposure in newborn rats.

Authors:  Serdar Demirgan; Onat Akyol; Zeynep Temel; Aslıhan Şengelen; Murat Pekmez; Ozancan Ulaş; Mehmet Salih Sevdi; Kerem Erkalp; Ayşin Selcan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-27       Impact factor: 3.000

Review 8.  Intranasal Insulin: a Treatment Strategy for Addiction.

Authors:  Bhavani Kashyap; Leah R Hanson; William H Frey Ii
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

Review 9.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939

10.  Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury.

Authors:  Haihong Zhou; Furong Sun; Mingqian Ou; Yu Zhang; Meijun Lin; Liqin Song; Yangsheng Yu; Haojie Liao; Weihao Fan; Huaijie Xing; Minhua Li; Kui Zhao; Xiaolian Wu; Yuanhong Sun; Chunmei Liang; Yujie Cai; Lili Cui
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.